ClinicalTrials.gg
RecruitingNCT07235384Updated Nov 4, 2026

A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis

A Phase 1 interventional study of ZL-1503 and Placebo in Atopic Dermatitis (AD), sponsored by Zai Lab (Shanghai) Co., Ltd.. Recruiting at 14 sites in 3 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Nov 4, 2026Eligibility revised2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 207 studies in Dermatitis, Atopic with a site in China — 65 open to participants now, 83 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Planned enrollment
138th of 191
84 · median 163
Started
2025
with 33 others
Phase 1
39 of 207
15 open now
Primary completion
2027-12
later than 60 of 82 live
Registered
170th of 207
by date

Among the 207 studies in Dermatitis, Atopic with a site in China, this one is the 138th largest by planned enrollment of the 191 interventional ones that give a count, is one of 34 that started in 2025, is one of 39 in phase 1, reaches primary completion later than 60 of the 82 other live ones, and was the 170th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

65 of the 207 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 207 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)

Read the detailed description

The study consists of two parts:

  • Part A: single ascending dose in healthy volunteers
  • Part B: multiple ascending doses in adult participants with moderate to severe AD
03

Conditions studied

  • Atopic Dermatitis (AD)

Browse trials for

Keywords

  • Atopic Dermatitis
04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part A:

    1. Healthy male and female volunteers, 18-65 years of age
    2. (BMI) between ≥ 18.5 and \< 32.5 kg/m2
    3. Negative pregnancy tests for women of .
  • Part B:

    1. 18-65 years of age;
    2. BMI between ≥18.5 and \<40.0 kg/m2
    3. Have a diagnosis of AD at least 12 months prior to Day 1;
    4. Moderate-to-severe AD at Screening and Baseline visit, defined as:

      1. Eczema Area and Severity Index (EASI) score ≥ 16;
      2. Affected Body Surface Area (BSA)≥ 10%;
      3. vIGA-AD™ score ≥ 3
    5. History of an inadequate response to treatment with topical medications
    6. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
    7. Negative pregnancy tests for women of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Part A and B:

    1. Significant health issues, such as positive tests for (HIV), virus (HCV), surface antigen (HBsAg), active tuberculosis, immunodeficiencies or diseases.
    2. History of major metabolic, liver, kidney, hematologic or other significant disorders.
    3. Abnormal (ECG) findings
    4. abnormal lab results, including low blood counts, or abnormal liver and kidney function, in the investigator's judgment, make the participant unsuitable for study participation.
    5. History of drug abuse or addiction within 6 months prior to screening
    6. Donated >500mL blood within 2 months of dosing.
  • For Part B only:

    1. Presence of dermatologic conditions and/or comorbidities that might confound the diagnosis of AD and/or might interfere with study assessments.
    2. Uncontrolled chronic disease that might require bursts of oral .
    3. Any other sound medical, psychiatric, and/or social reason as determined by the investigator.
    4. Smoke > 10 cigarettes or the equivalent (including electronic cigarettes) per day.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    ZL-1503: Participants will receive single ascending doses of ZL-1503

    Part A: Single Ascending Dose (SAD)

    Drug: ZL-1503 · Drug: Placebo

  • Experimental
    ZL-1503: Participants will receive multiple ascending doses of ZL-1503

    Part B: Multiple Ascending Dose (MAD)

    Drug: ZL-1503 · Drug: Placebo

Interventions

  • DrugZL-1503

    Healthy volunteers will receive ZL-1503.

  • DrugPlacebo

    Healthy volunteers will receive placebo.

  • DrugZL-1503

    Participants with moderate to severe atopic dermatitis will receive ZL-1503.

  • DrugPlacebo

    Participants with moderate to severe atopic dermatitis will receive placebo.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 48 weeks after last intervention

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 48 weeks after last intervention

  3. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 48 weeks after last intervention

  4. Number of participants with vital sign abnormalities

    Time frame: Up to 48 weeks after last intervention

  5. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 48 weeks after last intervention

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2027, 24 months after the start.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 24 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 28, 2027
CompletionEst.
Dec 28, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 China)
  • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
  • Dermatology Hospital of Jiangxi Province · Nanchang, China
Nov 4, 2026
Eligibility
1 exclusion criterion edited, 1 added, 1 removed
What changed in the criteria
Exclusion criteria
  • EditedClinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function, in the investigator's judgment, make the participant unsuitable for study participation.
  • RemovedCurrent smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.
  • AddedSmoke > 10 cigarettes or the equivalent (including electronic cigarettes) per day.
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added
    Show 2 added (2 China)
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
    • Dermatology Hospital of Jiangxi Province · Nanchang, China
    Eligibility 1 exclusion criterion edited, 1 added, 1 removed
    What changed in the criteria
    Exclusion criteria
    • EditedClinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function, in the investigator's judgment, make the participant unsuitable for study participation.
    • RemovedCurrent smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.
    • AddedSmoke > 10 cigarettes or the equivalent (including electronic cigarettes) per day.

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07235384
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Dec 1, 2025
Primary completion
Dec 28, 2027 (estimated)
Completion
Dec 28, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

ZaiLab Medical Director
Contact
ZaiLab_1503-001_StudyTeam@zailaboratory.com
+86 021-61632588

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion